These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3544114)

  • 1. [How to determine the optimal dosage of a drug].
    Juillet Y; Abadie E
    Rev Med Interne; 1986 Nov; Spec No():21-7. PubMed ID: 3544114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical trials in dermatology. The phase I trials].
    Czernielewski J; Queille-Roussel C; Duteil L; Verschoore M; Schaefer H; Revuz J; De Prost Y; Guillaume JC; Ortonne JP
    Therapie; 1991; 46(3):183-7. PubMed ID: 1792649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Determination of drug posology in pediatrics].
    Autret E; Vasmant D
    Therapie; 1995; 50(4):381-6. PubMed ID: 7482393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical trials of drugs without immediate therapeutic objectives].
    Cheymol G
    Ann Med Interne (Paris); 1987; 138(3):173-7. PubMed ID: 3619247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation and recommendations on adaptive dose-ranging trials: highlights from the PhRMA Adaptive Dose-Ranging Studies Working Group.
    Pinheiro J
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):47S-49S. PubMed ID: 20881216
    [No Abstract]   [Full Text] [Related]  

  • 6. Repeat administration of drugs as a means to assess the genetic component in pharmacological variability.
    Kalow W; Endrenyi L; Tang B
    Pharmacology; 1999 Jun; 58(6):281-4. PubMed ID: 10325572
    [No Abstract]   [Full Text] [Related]  

  • 7. Dose-finding studies in clinical drug development.
    Schmidt R
    Eur J Clin Pharmacol; 1988; 34(1):15-9. PubMed ID: 3360047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do we need highly sensitive analytical techniques in phase I?
    Singlas E
    Fundam Clin Pharmacol; 1990; 4 Suppl 2():135s-140s. PubMed ID: 2093624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug dosage optimization taking into account human circadian rhythms].
    Kudrin AN; Davydova ON; Zatsepilova TA; Riazhenov VV
    Sov Med; 1985; (10):37-41. PubMed ID: 3909447
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluating potential benefits of dose-exposure-response modeling for dose finding.
    Hsu CH
    Pharm Stat; 2009; 8(3):203-15. PubMed ID: 19629954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Important considerations for the clinical evaluation of drugs: appropriate dosing regimens.
    Finkel MJ
    Drug Intell Clin Pharm; 1984 Mar; 18(3):256-8. PubMed ID: 6365497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling approaches to dose estimation in children.
    Johnson TN
    Br J Clin Pharmacol; 2005 Jun; 59(6):663-9. PubMed ID: 15948929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study design and simulation approach.
    Läer S; Meibohm B
    Handb Exp Pharmacol; 2011; 205():125-48. PubMed ID: 21882109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines for clinical trials of psychotropic drugs June 1, 1977.
    Pharmakopsychiatr Neuropsychopharmakol; 1977 Jul; 10(4):205-31. PubMed ID: 360242
    [No Abstract]   [Full Text] [Related]  

  • 15. Are phase I studies without drug level determination acceptable?
    Morselli PL
    Fundam Clin Pharmacol; 1990; 4 Suppl 2():125s-133s. PubMed ID: 2093623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug efficacy--double-blind studies.
    Basmajian JV; Adler P; Ord RL
    J Rehabil; 1974; 40(5):26-30. PubMed ID: 4606453
    [No Abstract]   [Full Text] [Related]  

  • 17. Pediatric dose selection.
    Abernethy DR; Burckart GJ
    Clin Pharmacol Ther; 2010 Mar; 87(3):270-1. PubMed ID: 20160747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuing the use of the Cockcroft-Gault equation for drug dosing in patients with impaired renal function.
    Spruill WJ; Wade WE; Cobb HH
    Clin Pharmacol Ther; 2009 Nov; 86(5):468-70. PubMed ID: 19844221
    [No Abstract]   [Full Text] [Related]  

  • 19. [Methodology in phase I study].
    Ogawa M
    Gan To Kagaku Ryoho; 1982 Aug; 9(8):1489-91. PubMed ID: 7184457
    [No Abstract]   [Full Text] [Related]  

  • 20. Statistical problems in interpreting comparative bioavailability trials.
    Westlake WJ
    Int J Clin Pharmacol Biopharm; 1975 Jun; 11(4):342-5. PubMed ID: 1099025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.